Company Profile
PDS Biotechnology Corporation Stock Price, News & Catalysts
- Ticker:
- PDSB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.04 USD (-12.92%)
Close
Last updated: October 6, 2026
64.7M USD
Market cap
Why the stock is moving
Following the latest company update, “PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases”, PDSB closed down 12.9% at $1.04 on Oct 6, 2026. The move occurred in the trading session associated with this company update.
Company overview
Targeted Cancer Immunotherapy
PDS Biotechnology develops immunotherapies intended to activate antitumor immunity while directing immune stimulation toward the tumor microenvironment.
PDS0301
PDS0301 is a tumor-targeted interleukin-12 immunocytokine designed to enhance local immune activity while limiting systemic IL-12 exposure. It is now the company's lead internal development program.
Solid-Tumor Evidence
PDS0301 has been clinically evaluated in metastatic colorectal cancer, prostate cancer, and other solid tumors. Early data support further investigation in combinations intended to overcome treatment resistance.
PDS0101 Strategy
PDS Biotechnology discontinued internal funding of the VERSATILE-003 Phase 3 program and is seeking partnership or externally funded pathways for continued development of PDS0101.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of PDS Biotechnology Corporation (PDSB)?
PDS Biotechnology Corporation (PDSB) most recently closed at 1.04 USD, a -12.92% move versus the previous session.
What is the market cap of PDS Biotechnology Corporation (PDSB)?
PDS Biotechnology Corporation currently has a market capitalization of 64.7M USD on BioPharmSignal.
What does PDS Biotechnology Corporation do?
Targeted Cancer Immunotherapy PDS Biotechnology develops immunotherapies intended to activate antitumor immunity while directing immune stimulation toward the tumor microenvironment. PDS0301 PDS0301 is a tumor-targeted interleukin-12 immunocytokine designed to enhance local immune activity while limiting systemic IL-12 exposure. It is now the company's lead...
On which exchange is PDSB stock listed?
PDS Biotechnology Corporation (PDSB) is associated with NASDAQ, United States, Biopharma.
What is IL-12?
PDS0301 PDS0301 is a tumor-targeted interleukin-12 immunocytokine designed to enhance local immune activity while limiting systemic IL-12 exposure.
Which conditions is PDS Biotechnology Corporation targeting with IL-12?
PDS Biotechnology Corporation is associated with cancer therapeutics based on its company overview and current catalyst commentary.
What is VERSATILE-003?
PDS0101 Strategy PDS Biotechnology discontinued internal funding of the VERSATILE-003 Phase 3 program and is seeking partnership or externally funded pathways for continued development of PDS0101.
What is Targeted?
Targeted Cancer Immunotherapy PDS Biotechnology develops immunotherapies intended to activate antitumor immunity while directing immune stimulation toward the tumor microenvironment.